Stay updated on Azacitidine + Pembrolizumab in AML Clinical Trial
Sign up to get notified when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.

Latest updates to the Azacitidine + Pembrolizumab in AML Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded a clarifying note that publications are automatically filled from PubMed and updated the revision to v3.3.2.SummaryDifference0.1%

- Check24 days agoChange DetectedA site-wide government funding status notice has been removed. The core study details and contacts remain unchanged.SummaryDifference0.4%

- Check45 days agoChange DetectedThe Study Details page preserves the same core information as before (title, interventions, status, eligibility criteria, locations). Only minor formatting or layout adjustments are evident.SummaryDifference0.4%

- Check66 days agoChange DetectedAdded a government funding/operating-status notice and bumped version to v3.2.0, replacing the prior v3.1.0.SummaryDifference2%

- Check74 days agoChange DetectedUpgrade from v3.0.2 to v3.1.0, updating the page version identifier.SummaryDifference0.1%

- Check89 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed. No other substantive changes to pricing, timeslots, or named entities.SummaryDifference0.1%

Stay in the know with updates to Azacitidine + Pembrolizumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.